A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis-Reference-Cited by-同舟云学术

A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis

Published:2018-11-05 Issue:4 Volume:30 Page:333-339
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Kerdel Francisco A.¹,Draelos Zoe D.²,Tyring Stephen K.³,Lin Tina⁴,Pillai Radhakrishnan⁵

Affiliation:

1. Florida Academic Dermatology Centers Research and Education LLC, Coral Gables, FL, USA;

2. Dermatology Consulting Services, High Point, NC, USA;

3. Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA;

4. Ortho Dermatologics, Bridgewater, NJ, USA;

5. Dow Pharmaceutical Sciences Inc., Petaluma, CA, USA

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2018.1523362

Reference27 articles.

1. Guidelines of care for the management of psoriasis and psoriatic arthritis

2. Topical steroid risk analysis: Differentiating between physiologic and pathologic adrenal suppression

3. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities

4. Psoriasis: Improving adherence to topical therapy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and Efficacy of a Novel Combination Cream (GN-037) in Healthy Volunteers and Patients with Plaque Psoriasis: A Phase 1 Trial;Dermatology and Therapy;2023-06-10

2. Halobetasol propionate lotion 0.05% in patients 12 to 16 years 11 months of age with plaque psoriasis: Results of an open-label study evaluating adrenal suppression potential;JAAD International;2022-03

3. Recent Advances in Psoriasis Therapy: Trends and Future Prospects;Current Drug Targets;2021-11

4. New topical therapies for psoriasis;Dermatological Reviews;2021-08-05

5. Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants;J DRUGS DERMATOL;2021